A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors
Here, the authors provide a panel of medium-throughput assays to test potential drug candidates against different life cycle stages of Cryptosporidium with the goal to support a drug development pipeline that contains compounds with diverse molecular mechanisms of action.
Enregistré dans:
| Auteurs principaux: | Rajiv S. Jumani, Muhammad M. Hasan, Erin E. Stebbins, Liam Donnelly, Peter Miller, Connor Klopfer, Kovi Bessoff, Jose E. Teixeira, Melissa S. Love, Case W. McNamara, Christopher D. Huston |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2019
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/03437c7266734301bb9d6a058e5a30f9 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis
par: Christopher S. Lunde, et autres
Publié: (2019) -
Suits and Uniforms
par: Hasan Kösebalaban
Publié: (2004) -
Ruth Ellis’s Suit
par: Lynda Nead
Publié: (2021) -
Multilocus sequence subtyping and genetic structure of Cryptosporidium muris and Cryptosporidium andersoni.
par: Rongjun Wang, et autres
Publié: (2012) -
Familial Cancer Variant Prioritization Pipeline version 2 (FCVPPv2) applied to a papillary thyroid cancer family
par: Abhishek Kumar, et autres
Publié: (2018)